DeepX Diagnostics Inc.’s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions
DeepX Diagnostics Inc. to enter US market, having already performed over 180,000 skin lesions assessments in pharmacy and primary care to date in Europe. WASHINGTON, June 6, 2023 /PRNewswire/ — DeepX Diagnostics Inc., the skin cancer teledermatology and diagnostics company, announced today that its digital dermatoscope DermoSightTM received clearance from the US Food and Drug Administration (FDA) for … Read more